Effect of stobadine on Cu++-mediated oxidation of low-density lipoprotein

被引:23
作者
Horakova, L
Giessauf, A
Raber, G
Esterbauer, H
机构
[1] GRAZ UNIV, INST ANALYT CHEM, A-8010 GRAZ, AUSTRIA
[2] SLOVAK ACAD SCI, INST EXPT PHARMACOL, BRATISLAVA 84216, SLOVAKIA
关键词
LDL; stobadine; lipid peroxidation; tryptophan; antioxidant;
D O I
10.1016/0006-2952(96)00033-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pyridoindole derivative stobadine [(-)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexa pyrido(4,3b) indole] has been described as a drug with antihypoxic and antiarrhythmic cardioprotective properties. The antioxidative properties of this compound were studied during Cu++-mediated low-density lipoprotein (LDL) oxidation. Stobadine (concentration 0-5 mu M) prolonged the lag phase (in min produced by one molecule antioxidant per LDL particle) as measured by diene formation more effectively than did ascorbate, trolox, or alpha tocopherol. It also has the ability to decrease the rate of diene formation during the propagation phase very efficiently. Diene formation, Trp destruction, and alpha-tocopherol consumption were measured in the presence and absence of stobadine. Stobadine (10 mu M) did not influence tocopherol consumption during oxidation and the Trp fluorescence quenching of Cu++ was not influenced by this compound. From these results, as well as polarographic measurements, we conclude that the antioxidative effect of stobadine is not simply a result of Cu++-ion complexation. In contrast to ascorbate, this compound is stable in the presence of Cu++. Stobadine inhibits the oxidation of LDL-Trp residues very efficiently eia its radical scavenging properties, and may even have the ability to reduce Trp radicals to tryptophan. The concentration of stobadine used for LDL oxidation was in the range found in plasma (stobadine given p.o. in human and rats results in plasma concentrations between 0.2-3.9 mu M).
引用
收藏
页码:1277 / 1282
页数:6
相关论文
共 24 条
[21]  
STEFEK M, 1994, CAN J PHYSL PHARM S1, V72, P591
[22]   ANTIOXIDANTS IN THE PREVENTION OF HUMAN ATHEROSCLEROSIS - SUMMARY OF THE PROCEEDINGS OF A NATIONAL-HEART-LUNG-AND-BLOOD-INSTITUTE WORKSHOP - SEPTEMBER 5-6, 1991, BETHESDA, MARYLAND [J].
STEINBERG, D ;
BERLINER, JA ;
BURTON, GW ;
CAREW, TE ;
CHAIT, A ;
CHISOLM, GM ;
ESTERBAUER, H ;
FOGELMAN, AM ;
FOX, PL ;
FURBERG, CD ;
GAZIANO, JM ;
GEY, KF ;
GRUNDY, SM ;
HARLAN, WR ;
HAVEL, RJ ;
HENNEKENS, CH ;
HOFF, HF ;
JACKSON, RL ;
KAYDEN, HJ ;
KEECH, A ;
KRINSKY, NI ;
MANSON, J ;
PARTHASARATHY, S ;
PROBSTFIELD, J ;
PRYOR, WA ;
RIFKIND, B ;
STADTMAN, ER ;
WALLACE, RB ;
WITZTUM, JL ;
YLAHERTTUALA, S ;
YUSUF, S .
CIRCULATION, 1992, 85 (06) :2338-2344
[23]  
STEINBERG D, 1989, NEW ENGL J MED, V320, P915
[24]  
STOLC S, 1994, PHARM COMMUN, V4, P277